PHOENIX, Ariz., Nov. 06, 2018 (GLOBE NEWSWIRE) — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) (the “Company”) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. CEO & Co-Founder, Eyal Barad, talked with Stock Day’s Everett Jolly.
“Cannabics Pharmaceuticals started about 5 years ago and today is mostly focused on the palliative and anti-tumor effects cannabinoids with cancer,” explained Barad. “We are truly focused on cancer, both the side effects and anti-tumor effects which we have found to be effectives in our studies.”
Jolly mentioned that many cannabis companies have come on Stock Day but rarely do they have a cancer centric focus. He asked Barad what his overall goal for fighting cancer would be.
“We started a study about 4-years-ago with one of the leading science universities in Israel, where we did drug sensitivity with various cannabinoids and various cancers and this is what got us going because we found that various ratios of various cannabinoids have different apoptotic effects on different cancers”
Barad went on to say after the study, they wrote patents on the subject and developed a lab in Israel. He said they hope to one day find specific combinations for specific cancers in specific people.
Jolly then mentioned the company’s pilot study on anorexia. Barad said they have summarized the first process of the clinical trial and that the results have enticed them to go to the next level and expand the study.
“In anorexic patients, we were able to improve the appetite and cause some weight gain,” explained Barad. “There was overall improvement in life quality for the patient. We are very excited about that.”
Jolly then asked about Cannabics Pharmaceutical’s partnership with Seedo, a lab that has developed an automated robot for growing personalized medical marijuana in people’s homes.
“We find that very exciting because we are able to tap in and collect a whole bunch of data from people and getting involved in what different strains are and how they are affecting different people,” said Barad. “One of the visions we have together is taking that to the next stage, taking it from the personalized to a more modular commercial product.”
Jolly then asked about artificial intelligence in the cannabinoid industry and the possibilities. Barad said data is the key.
“Drug discovery companies are now moving very swiftly into analyzing big data and being able to come up with specific medications for specific diseases and cannabis creates a very big challenge,” Barad explained. “There are many cannabinoids, which we are not familiar with all of them, and when you say cancer, it’s not just one disease. It’s many, many diseases.”
Jolly then turned to the direct offering of $7.5 million, he wanted to know what the funds will be used for. Barad said they have big plans to continue to build out their cannabinoid library.
“We want to add more expertise on our staff across different fields, we want to advance our clinical studies and put more into place, we are looking at developing more palliative products, beside our slow release tablet that we have currently selling in Colorado. So, we have big plans ahead and of course we are working to find anti-tumor properties and come out with specific medicine for that.”
Jolly then asked about the recent law that just went into effect in Canada, legalizing marijuana. He asked Barad how that will impact the medical market.
“I think it’s a step in legitimizing our work, we feel very fortunate what we are doing today. A few years back we couldn’t imagine being able to do this. We’ve been licensed in Israel for the past 4 years to do R and D in cannabinoids, which has enabled us to take big steps and even be leaders in the field. Canada is quickly catching up. You see there will be pressure on the U.S. to come into the game.”
To listen to the entire interview, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-eyal-barad-of-cannabics-pharmaceuticals-inc-otcqb-cnbx/
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
